Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review

Pediatric Dermatology
Kathryn AndersonLeslie Castelo-Soccio

Abstract

Severe atopic dermatitis (AD) may require systemic immunomodulatory agents to control symptoms. A lack of evidence and guidelines for systemic AD therapy in children has led to variability in agents selected and uncertainty in their comparative efficacy and safety. Evaluation of the efficacy of methotrexate in children with severe AD was performed. We performed a retrospective chart review of 55 pediatric patients seen at Children's Hospital of Philadelphia that measured improvement using the Investigator's Global Assessment (IGA), a scale that rates AD symptoms from 0 to 5. About 76% of patients showed improvement with methotrexate. Mean baseline IGA of all patients was 4.18. After 6-9 months of treatment, this improved to 2.94. There was additional improvement to a mean IGA score of 2.39 after 12-15 months of treatment. At the final visit before each patient stopped methotrexate, the mean IGA score was 2.71. Approximately 50% of patients experienced minor side effects with gastrointestinal side effects the most common. In a diverse patient population, safety and efficacy of methotrexate was demonstrated. Significant improvement in IGA was noted for the majority after 6-9 months of therapy with further improvement when continu...Continue Reading

References

Mar 22, 2002·Journal of the American Academy of Dermatology·Lawrence F EichenfieldMichael Graeber
Jul 17, 2013·The British Journal of Dermatology·L E ProudfootUNKNOWN European Dermato-Epidemiology Network (EDEN)
Mar 8, 2014·International Journal of Dermatology·Maneka DeoMarius Rademaker
Dec 22, 2015·Journal of the American Academy of Dermatology·Masaki FutamuraEric L Simpson
Dec 3, 2016·Indian Journal of Dermatology·Dharshini Sathishkumar, Celia Moss
May 30, 2017·Drug Design, Development and Therapy·Angelo Massimiliano D'ErmeAndrea Chiricozzi
Jul 22, 2017·Pediatric Dermatology·Veronika DvorakovaAlan D Irvine
Jun 8, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allerg

❮ Previous
Next ❯

Citations

Oct 1, 2019·Pediatric Dermatology·Stephanie C Blake, Dedee F Murrell
Nov 19, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force
Apr 12, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Jennifer B MancusoLawrence F Eichenfield
May 25, 2021·Immunopharmacology and Immunotoxicology·Yuying GuoXin Liu
Jun 22, 2021·The Journal of Dermatological Treatment·Tamar HajarTeri M Greiling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.